Mini Review

Nanotoxicology: Assessing the Safety of Nanoparticles in Biomedical Applications

Dinesh Kulkarni

Department of Pharmaceutics,
BSBSS College of Pharmacy,
Jodhpur, Rajasthan, India.

Correspondence:
Dr. Dinesh Kulkarni,
Department of Pharmaceutics,
BSBSS College of Pharmacy,
Jodhpur, Rajasthan, India.
E-id:kulkarni.dinesh4323@gmail.com

How to cite this article:
Kulkarni D. Nanotoxicology: Assessing the Safety of Nanoparticles in Biomedical Applications. Innov Pharm Planet (IP-Planet) 2020;8(4):31-33.

Source of Support: Nil.
Conflicts of Interest: None declared.

Date of Submission: 29-10-2020
Date of Revision: 21-11-2020
Date of Acceptance: 02-12-2020

Abstract

The advent of nanotechnology has transformed biomedical applications, offering groundbreaking advancements in drug delivery, imaging, and diagnostics. Nanoparticles (NPs) provide unique physicochemical properties, such as high surface area-to-volume ratio and tunable surface chemistry, which enhance their biomedical efficacy. However, the widespread use of NPs raises concerns regarding their potential toxicological effects, leading to the emergence of nanotoxicology as a critical field of study.

This review delves into the mechanisms of nanoparticle-induced toxicity, including oxidative stress, inflammation, genotoxicity, and cellular dysfunction. The toxic effects of NPs are influenced by their size, shape, surface charge, composition, and aggregation state, which dictate their interactions with biological systems. Various exposure routes, including inhalation, ingestion, dermal contact, and systemic administration, further modulate toxicity outcomes.

To ensure safe biomedical applications, rigorous assessment methodologies such as in vitro assays, in vivo studies, and computational models are employed to evaluate NP biocompatibility and toxicity. Furthermore, strategies to mitigate risks—such as surface modifications, biocompatible coatings, and dose optimization—are discussed to enhance NP safety profiles.

By critically analyzing existing literature, this article provides insights into the current understanding of nanoparticle toxicity and its implications in biomedical fields. Addressing these concerns is vital for the safe and sustainable development of nanotechnology-based therapeutics and diagnostics. Continued research and regulatory frameworks are essential to balance innovation with safety, ensuring that nanomedicine can achieve its full potential without compromising human health.

Keywords: Nanotoxicology, Nanoparticle Safety, Biomedical Applications. Toxicity Mechanisms, Risk Assessment

Introduction

Nanotechnology has emerged as a transformative discipline, leveraging the unique physicochemical properties of nanoparticles (NPs) to revolutionize various scientific domains, particularly in biomedicine. Nanoparticles, characterized by their nanoscale dimensions and high surface area-to-volume ratio, exhibit properties that differ significantly from their bulk counterparts. These properties include enhanced reactivity, tunable optical behavior, and increased surface functionalization potential, making them ideal candidates for biomedical applications such as targeted drug delivery, advanced imaging, and biosensing.[1]

In drug delivery, nanoparticles offer the potential for precise targeting of therapeutic agents, reducing systemic side effects, and improving drug efficacy. For instance, liposomal formulations have enabled the encapsulation of chemotherapeutic agents, enhancing their delivery to cancer cells while sparing healthy tissue.[2] Similarly, in diagnostics, gold nanoparticles have been employed as contrast agents in imaging techniques, providing superior resolution due to their optical properties.[3]

However, these same properties that confer immense benefits also present potential risks when nanoparticles interact with biological systems. Their small size facilitates cellular uptake, but it can also

Access this article online

Website: https://innovationaljournals.com/index.php/ip | e-ISSN: 2348-7275

lead to unintended bioaccumulation and toxicity. Additionally, the ability of NPs to generate reactive oxygen species (ROS) poses challenges in terms of oxidative stress and inflammatory responses.[4] These concerns underscore the need for nanotoxicology—a specialized field dedicated to understanding the biological interactions, biodistribution, and long-term effects of nanoparticles.

Nanotoxicology encompasses the study of how nanoparticle properties—such as size, shape, surface charge, and material composition—influence their interactions with cells, tissues, and organs. It seeks to elucidate mechanisms of toxicity, including oxidative stress, genotoxicity, and immunomodulation.[5] By identifying these mechanisms, researchers aim to establish guidelines for the safe design and application of nanoparticles in biomedical contexts. This review explores the state of nanotoxicology as of 2020, highlighting key findings and methodologies that contribute to the safe integration of nanotechnology in healthcare.

Mechanisms of Nanoparticle Toxicity

Nanoparticles can exhibit toxicity through several mechanisms, primarily influenced by their size, surface chemistry, and reactivity.

Nanoparticles can generate reactive oxygen species (ROS), leading to oxidative stress, DNA damage, and cell death. Metal oxide nanoparticles such as titanium dioxide (TiO2) and zinc oxide (ZnO) are known for their ROS-inducing properties, which can disrupt mitochondrial function.[6] Cellular uptake of nanoparticles often occurs through endocytosis. While this enables their biomedical use, it can also cause cytotoxicity. For instance, cationic nanoparticles have been shown to disrupt lipid bilayers, leading to membrane damage.[7] Additionally, nanoparticles can modulate the immune system by activating inflammatory pathways or suppressing immune responses. Carbon nanotubes, for example, are associated with chronic inflammation due to their high aspect ratio and bio persistence.[8] Some nanoparticles, such as silver nanoparticles, can interact directly with DNA, causing genotoxic effects like structural damage and chromosomal aberrations.[1]

Routes of Exposure and Biodistribution

Nanoparticles enter biological systems through various routes, each influencing their biodistribution and potential toxicity. Inhalation is a common route of exposure for nanoparticles, particularly those present in aerosols or workplace environments. Once inhaled, nanoparticles such as carbon-based materials and metal oxides can accumulate in the lungs, causing pulmonary inflammation and fibrosis.[9] Ingestion occurs when nanoparticles are introduced into the gastrointestinal tract via food additives or nanomedicines. Their absorption and biodistribution depend on surface properties, often leading to organ accumulation.[10] Dermal absorption is another route of exposure, particularly relevant to cosmetics and sunscreens containing TiO2 or ZnO nanoparticles. Studies have raised concerns about percutaneous penetration, especially with prolonged use.[5] Finally, injection as a direct route for drug delivery ensures systemic exposure, necessitating careful assessment of biodistribution and accumulation, particularly in organs like the liver and spleen.[11]

Methodologies for Assessing Nanotoxicity

Evaluating the safety of nanoparticles requires diverse methodologies to capture their complex interactions with biological systems.

In vitro studies are foundational for nanotoxicity assessment. Cytotoxicity assays such as MTT and LDH release tests evaluate cell viability in response to nanoparticles. Genotoxicity assays, including the comet assay, are used to measure DNA damage. In vivo, studies complement in vitro findings by providing insights into systemic effects, biodistribution, and chronic toxicity in animal models. Computational models, such as Quantitative Structure-Activity Relationship (QSAR) modeling, are increasingly employed to predict nanoparticle behaviour and toxicity, aiding in risk assessment. Advanced imaging techniques like transmission electron microscopy (TEM) and fluorescence microscopy are essential for tracking nanoparticle interactions with cells and tissues, providing detailed spatial information.

Minimizing Nanotoxicity

Strategies to reduce nanoparticle toxicity are critical to their safe application in biomedicine.

Surface functionalization, such as coating nanoparticles with

biocompatible polymers like polyethylene glycol (PEG), reduces immune recognition and enhances safety. Optimization of size and shape also plays a crucial role, as smaller, spherical nanoparticles with well-defined surfaces are less likely to aggregate or cause adverse effects. Green synthesis approaches using plant-based or microbial methods have been explored to minimize residual toxic reagents and improve biocompatibility.

Case Studies in Biomedical Applications

The potential of nanoparticles in medicine is evident in their application to drug delivery, diagnostics, and tissue engineering. In drug delivery, liposomal nanoparticles have proven effective in reducing systemic toxicity in cancer therapy compared to traditional chemotherapy. In diagnostics, gold nanoparticles are widely used as imaging contrast agents due to their inert nature when appropriately coated. Tissue engineering applications often involve nanocomposites as scaffolds, which require rigorous testing to ensure compatibility and minimize immune rejection.

Conclusion and Future Directions

Nanoparticles hold immense promise for transforming biomedical applications, but their safety profiles must be meticulously understood. The field of nanotoxicology has advanced significantly, shedding light on the mechanisms and routes of nanoparticle toxicity. However, challenges remain, particularly in standardizing methodologies and translating findings into universally applicable safety guidelines. Future research should prioritize long-term studies, establish regulatory frameworks, and develop standardized testing protocols to enable the safe integration of nanotechnology into healthcare.

References

1. Donaldson, K., Murphy, F. A., Duffin, R., & Poland, C. A. (2010). Asbestos, carbon nanotubes, and the pleural mesothelium: a review of the hypothesis regarding fiber-induced mesothelioma. Particle and Fibre Toxicology, 7, 5
2. Asharani, P. V., Hande, M. P., & Valiyaveettil, S. (2009). Anti-proliferative activity of silver nanoparticles. Biomaterials, 30(31), 6341-6350.
3. Oberdörster, G., Oberdörster, E., & Oberdörster, J. (2005). Nanotoxicology: An emerging discipline evolving from studies of ultrafine particles. Environmental Health Perspectives, 113(7), 823-839.
4. Monteiro-Riviere, N. A., & Riviere, J. E. (2007). Interaction of nanomaterials with skin: Aspects of absorption and toxicology. Nanotoxicology, 1(3), 201-209.
5. Poland, C. A., Duffin, R., Kinloch, I., Maynard, A., Wallace, W. A., Seaton, A., & Donaldson, K. (2008). Carbon nanotubes introduced into the abdominal cavity of mice show asbestos-like pathogenicity in a pilot study. Nature Nanotechnology, 3(7), 423-428.
6. Manke A, Wang L, Rojanasakul Y. Mechanisms of nanoparticle-induced oxidative stress and toxicity. Biomed Res Int. 2013;2013:942916. doi: 10.1155/2013/942916. Epub 2013 Aug 20. PMID: 24027766; PMCID: PMC3762079.
7. Lin, W., Huang, Y. W., Zhou, X. D., & Ma, Y. (2009). In vitro toxicity of silica nanoparticles in human lung cancer cells. Toxicology and Applied Pharmacology, 217(3), 252-259.
8. Dong J, Ma Q. Integration of inflammation, fibrosis, and cancer induced by carbon nanotubes. Nanotoxicology. 2019 Nov;13(9):1244-1274.
9. Lu X, Zhu T, Chen C, Liu Y. Right or left: the role of nanoparticles in pulmonary diseases. Int J Mol Sci. 2014 Sep 29;15(10):17577-600.
10. Chen, M., & von Mikecz, A. (2006). Nanoparticle-induced cell damage. Experimental and Molecular Pathology, 80(3), 183-188.
11. Choi, H. S., Liu, W., Misra, P., Tanaka, E., Zimmer, J. P., Ipe, B. I., & Bawendi, M. G. (2007). Renal clearance of quantum dots. Nature Biotechnology, 25(10), 1165-1170.